Printer Friendly

ONCOR APPOINTS GLENN P. FREIBERG VICE PRESIDENT FOR CLINICAL AFFAIRS

ONCOR APPOINTS GLENN P. FREIBERG VICE PRESIDENT FOR CLINICAL AFFAIRS
 GAITHERSBURG, Md., March 19 /PRNewswire/ -- The appointment of Glen Paul Freiberg as vice president for clinical and regulatory affairs of Oncor, Inc. (NASDAQ: ONCR) was announced today by Stephen Turner, the company's chairman and chief executive officer. Freiberg joins in this new position from Boehringer Mannheim Corporation where he was group director for regulatory affairs and quality assurance.
 Turner said: "Mr. Freiberg will be responsible for regulatory affairs, clinical evaluations and quality assurance. He will be overseeing clinical trials now underway as well as current and future programs for FDA approvals. His broad experience in the health care industry will be invaluable to Oncor as we aggressively pursue the development and commercialization of DNA Probe Systems for the early detection and management of cancer and other genetic diseases. New products which will assist in the diagnosis of bladder, breast, colon and prostate cancer are now undergoing development and/or clinical trials in preparation for FDA submission and approvals over the next three years."
 At Boehringer Mannheim, Freiberg was responsible for all aspects of product launch approvals including PMAs, PLAs, 510(k)s, master files and QA systems and documentation. He was also a member of the technology assessment team. Prior to joining Boehringer Mannheim in 1986, he held responsible positions in the areas of regulatory affairs, quality assurance and safety compliance with Curtin Matheson Scientific, Inc. The Coulter Corporation and The Upjohn Company. From 1976 to 1980, he served as a consumer safety officer with the U.S. Food and Drug Administration in the New England District.
 "After more than 16 years years of government and industry experience," said Freiberg, "joining Oncor, the leading DNA probe company, is a unique opportunity. I am excited by the challenge to efficiently move our revolutionary oncology and genetic research products into the clinical environment, thereby making an enduring contribution to our customers and their patients."
 Freiberg is an active participant in industry associations and is a frequent speaker at educational and trade-group seminars, He is chairman of the Health Industry Manufacturers Association's in Vitro Diagnostics Task Force and is the industry representative on the FDA's clinical chemistry and toxicology panel.
 Freiberg is a graduate of the University of Colorado, Boulder with a Bachelor's degree in biology and a Master's degree in microbiology.
 Oncor, Inc. is a leading manufacturer an marketer of DNA probes for the detection of cancer and other genetic diseases.
 -0- 3/19/92
 /CONTACT: Stephen Turner, chairman and CEO of Oncor, 301-963-3500/
 (ONCR) CO: Oncor Inc. ST: Maryland IN: MTC SU: PER


TQ-AH -- NY047 -- 9686 03/19/92 12:26 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 19, 1992
Words:441
Previous Article:FPL ANNOUNCES SALE OF PREFERRED STOCK
Next Article:REPOSSESSION AUCTION, INC., REPORTS NASDAQ NMS LISTING AND EARNINGS FOR THE YEAR ENDED DEC. 31, 1991
Topics:


Related Articles
ONCOR, INC. ANNOUNCES THE APPOINTMENT OF DR. KENNETH W. CULVER AS DIRECTOR OF GENE THERAPY RESEARCH, CLINICAL AFFAIRS FOR ONCORPHARM, INC.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters